Stockreport

H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program [Yahoo! Finance]

Lexeo Therapeutics, Inc.  (LXEO) 
PDF TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target for LXEO to $10 from $13 and maintained a Buy rating. The firm belie [Read more]